MVADS 2025 Preliminary Final Programme
For further information on this event please contact us.
Day One
Tuesday 8th April 2025
09.15 Onwards
Registration
09.55
Welcome & Opening Remarks
James Brewer
(University of Glasgow, Glasgow, Scotland, UK)
SESSION 1:
OPENING PLENARY
Moderator: James Brewer
(University of Glasgow, Glasgow, Scotland, UK)
10.00-10.30
‘Advances and challenges in vaccine adjuvants’
Derek O’Hagan
(GSK Biologicals, Rockville, Maryland, USA)
10.30-11.00
‘AI-assisted screening and design of vaccine adjuvant’
Ken Ishii
(University of Tokyo, Tokyo, Japan)
11.00-11.15
Coffee Break & Posters Set-Up
SESSION 2:
PLENARY
Moderator: Gabriel Pedersen
(Statens Serum Institute, Copenhagen, Denmark)
11.15-11.45
‘Can we improve the efficacy of mRNA vaccines through targeting?’
Yvonne Perrie
(University of Strathclyde, Glasgow, Scotland, UK)
11.45-12.15
‘Targeting of inflammasomes and interferons for enhanced adjuvant efficacy’
Edward Lavelle
(Trinity College Dublin, Dublin, Ireland)
12.15-12.45
‘A promising dendritic cell targeting vaccine delivery platform for influenza and COVID19’
Sylvie Alonso
(National University of Singapore, Singapore)
12.45-13.30
Lunch Break & Posters
SESSION 3:
Moderator: John Oxford
(Queen Mary University London, London, UK)
13.30-14.00
‘Administration route is decisive for the resulting immune fingerprint of vaccine adjuvants. Case story with CD8 T-cell inducing vaccine adjuvant CAF09b’
Dennis Christensen
(CRODA, Frederikssund, Hovedstaden, Denmark)
14.00-14.20
‘Molecular signatures of an adjuvanted vaccine candidate’
Laurent Beloeil
(BioAster / Sanofi Vaccines, Lyon, France)
14.20-14.50
‘CAF10b – a liposomal adjuvant that induces sustained Th1/Th17 vaccine memory in mice and non-human primates’
Gabriel Pedersen
(Statens Serum Institute, Copenhagen, Denmark)
14.50-15.10
Tea Break & Posters
SESSION 4:
Moderator: Erik Lindblad
(Inari Consult ApS, Denmark)
15.10-15.30
‘Novel QTAP-nanovaccines against emerging avian influenza infections’
Adel Talaat
(University of Wisconsin-Madison, Wisconsin, USA)
15.30-15.50
‘Engineered aluminum-based combination adjuvants’
Bingbing Sun
(Dalian University of Technology, Dalian, China)
15.50-16.10
‘Virus-like particle based vaccines against opioids’
Isabella G. Romano
(University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA)
16.10-16.30
‘TRAP-cage: A groundbreaking synthetic VLP platform for vaccine development’
Isabela Stupka
(nCage Therapeutics, Krakow, Poland)
16.30-17.00
‘Novel 3rd generation pattern recognition receptor agonists for improved vaccine performance and tolerability’
Omer Rasheed
(InImmune Corp/SPI Pharma, Missoula, Montana, USA)
Day Two
Wednesday 9th April 2025
SESSION 5:
Moderator: Edward Lavelle
(Trinity College Dublin, Dublin, Ireland)
09.15-09.45
‘Companion animals as a promising intermediate for the development of therapeutic vaccines in humans’
Martin Bachmann
(University Hospital of Bern, Inselspital, Bern, Switzerland)
09.45-10.05
‘Paced immune activation by AS04 drives superior cross-protective antibody response in Cervarix®’
Valentino D’Onofrio
(Center for Vaccinology, Ghent University, Ghent, Belgium)
10.05-10.25
‘Sublingual dissolving microneedle-based vaccine for inducing mucosal immunity against SARS-CoV-2’
Hyungil Jung
(Yonsei University Seoul, South Korea)
10.25-10.45
Coffee Break & Posters
SESSION 6:
Moderator: Yvonne Perrie
(University of Strathclyde, Glasgow, Scotland, UK)
10.45-11.15
‘How adjuvants can be delivered by dissolvable microneedle patches’
Anne Moore
(University College Cork, Cork, Ireland)
11.15-12.15
‘Unveiling the many facets of VLPs: Advancing therapeutic cancer vaccines’
Mona O. Mohsen
(University Hospital of Bern, Inselspital, Bern, Switzerland)
12.15-12.35
‘Liposomal adjuvant eliciting local T cell responses after intranasal administration’
Katharina Wørzner
(Statens Serum Institut, Copenhagen, Denmark)
12.35-13.00
‘Naturally sourced saponin adjuvants, enabling billions of vaccine doses every year’
Damian Hiley
(Desert King, Chula Vista, California, USA)
13.00-13.45
Lunch Break & Posters
SESSION 7:
Moderator: Derek O’Hagan
(GSK Biologicals, Rockville, Maryland, USA)
13.45-14.15
‘Understanding the within-host biology of the pathogen to design better vaccines and immune therapeutics’
Pietro Mastroeni
(University of Cambridge, Cambridge, UK)
14.15-14.45
‘New assays to evaluate immunogenicity of new vaccines’
Emanuele Montomoli
(VisMederi Srl, Siena, Italy)
14.45-15.05
‘Alum strikes back: The limited capacity of Nanoalum in inducing cell death pathways’
Arianna Raponi
(University of Glasgow, Glasgow, Scotland, UK)
15.05-15.20
Tea Break & Posters
SESSION 8:
Moderator: Virgil Schijns
(SwiftPharma BV, Ghent, Belgium)
15.20-15.50
‘Genetic adjuvants in replicating single-cycle adenovirus vectors amplify systemic and mucosal immune responses against HIV-1’
William E. Matchett, Goda Baddage Rakitha Malewana, Haley Mudrick, Michael J. Medlyn and Michael A. Barry
(Mayo Clinic, Rochester, Minnesota, USA)
15.50-16.20
‘Exploring the cationic liposome, CAF04, as a delivery system for mRNA’
Signe Schmidt
(Statens Serum Institut, Copenhagen, Denmark)
16.20-16.50
‘Understanding the enhanced immune responses to high-density microarray patch vaccination through spacial transcriptomics and antibody repertoire analysis’
David Muller
(University of Queensland, Brisbane, Australia)
Day Three
Thursday 10th April 2025
SESSION 9:
Moderator: Naveen Surendran
(Pfizer, Pearl River, New York, USA)
09.30-10.00
‘Next-generation saponins for sustainable and affordable adjuvant systems’
Rasmus Münter
(CRODA, Frederikssund, Hovedstaden, Denmark)
10.00-10.15
‘Immune stimulating properties of LNP formulations containing a PEG alternative’
Raphaela P. Semper, Dwain van Zyl, Livia Palmerston Mendes, Christine Rueckert and Patrick Baumhof
(CureVac SE 72076, Tübingen, Germany)
10.15-10.45
‘Novel encoded adjuvants for genetic vaccines’
Emanuele Sasso
(University of Naples Federico II, Naples, Italy)
10.45-11.20
Coffee Break & Posters
SESSION 10:
Moderator: Moderator: Martin Bachmann
(University Hospital of Bern, Inselspital, Bern, Switzerland)
11.20-11.40
‘Clinical-stage dissolvable microarray technology for pandemic preparedness and global health equity’
Steven Damon
(Micron Biomedical, Atlanta, Georgia, USA)
11.40-12.00
‘Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T cell responses and anti-tumour immunity by targeting conventional type 1 dendritic cells’
Jorge Huete-Carrasco
(Trinity College Dublin, Ireland)
12.00-12.20
‘Developing and optimising a translational, adjuvant-screening pipeline’
Utku Gunes
(University of Glasgow, Glasgow, Scotland, UK)
12.20-13.30
Lunch Break & Posters Breakdown
SESSION 11:
CLOSING PLENARY SESSION
Moderator: James Brewer
(University of Glasgow, Glasgow, Scotland, UK)
13.30-14,00
‘Different faces of immune memory in the lung following influenza virus infection’
Megan Mcleod
(University of Glasgow, Glasgow, Scotland, UK)
14.00-14.30
‘Can we now repeat the WHO smallpox eradication campaign of 1980 and extend the science and principles to other important virus threats?’
John Oxford
(Queen Mary University London, London, UK)
14.30-15.00
Closing Plenary Presentation:
‘Understanding adjuvant basic immunology to direct rational adjuvant discovery’
Professor James Brewer
(University of Glasgow, Glasgow, Scotland, UK)
15.00
Closing Remarks & Departure
Posters
Poster 101
‘Immune stimulating properties of LNP formulations containing a PEG alternative’
Raphaela P. Semper, Dwain van Zyl, Livia Palmerston Mendes, Christine Rueckert and Patrick Baumhof
(CureVac SE 72076, Tübingen, Germany)
Poster 102
‘MONTANIDE™ ISA 51 VG, an open access adjuvant dedicated to therapeutic vaccines’
Nada Zehrouni1, Jaymes Bryant Tibig1,2, Dorine Hello1 and Hocine Nouari1
(1 SEPPIC SA, La Garenne Colombes, France; 2 Université Claude Bernard Lyon 1, Villeurbanne, France)
Poster 103
‘VFI Adjuvants for Global Health’
Léa Simon, Célia Lebas, Livia Brunner and Thomas Courant
(Vaccine Formulation Institute, Plan-les-Ouates, Switzerland)
Poster 104
‘Exploring the potential of TRAP-Cage as a next-generation vaccine platform’
Szymon Gaweł1, Izabela Stupka1, Sylwia Świątek1, Ivan Campeotto2, Janet Daly3, Monika Jakubowska4, Agnieszka Dąbrowska4, Krzysztof Pyrć4 and Jonathan G. Heddle1
(1 nCage Therapeutics, Kraków, Poland; 2 School of Bioscience, Division of Microbiology, Brewing and Biotechnology, University of Nottingham, Nottingham, UK; 3 School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK; 4 Jagiellonian University, Kraków, Poland)
Poster 105
‘Dendritic cell targeting of poloxamer micelles for vaccine delivery’
Ildikó Szabó1, Szabolcs Gellény1, Gergő Gyulai1,2 and Kata Horváti1
(1 MTA–HUN-REN TTK Lendület “Momentum” Peptide-Based Vaccines Research Group, Institute of Materials and Environmental Chemistry, 2 HUN-REN Research Centre for Natural Sciences, Budapest, Hungary)
Poster 106
‘Formation of emulsion adjuvants of varying sizes and compositions using Tee Mixing’
Marissa Bradley
(MERCK, West Point, Pennsylvania, USA)
Poster 107
‘The liposome-based adjuvant LMQ activates the NLRP3 Inflammasome in in vitro models of ageing’
Alexandra Sanchez-Martinez
(University of Surrey, Guildford, Surrey, UK)
This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.